Clinical Trial Update: Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating brentuximab vedotin in combination chemotherapy for CD30-positive peripheral T-cell lymphomas reports results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma Alk-negative
• Anaplastic Large Cell Lymphoma Alk-positive
• Angioimmunoblastic T-cell Lymphoma
• Enteropathy-associated T-cell Lymphoma
• Hepatosplenic T-cell Lymphoma
• Mature T-cell and Nk-cell Non-hodgkin Lymphoma
• Peripheral T-cell Lymphoma
• T-cell Leukemia Lymphoma

Drugs mentioned

• Brentuximab vedotin (Adcetris) (brentuximab vedotin)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-04-19